eMedicine Specialties > Infectious Diseases > Mycobacterial Infections

Mycobacterium Kansasii: Differential Diagnoses & Workup

Author: Janak Koirala, MD, MPH, FACP, Associate Professor, Department of Internal Medicine, Division of Infectious Diseases, Southern Illinois University School of Medicine
Contributor Information and Disclosures

Updated: Mar 18, 2009

Differential Diagnoses

Actinomycosis
Sporotrichosis
Aspergillosis
Tuberculosis
Histoplasmosis
Mycobacterium Avium-Intracellulare
Pneumonia, Bacterial

Other Problems to Be Considered

Mycobacterium scrofulaceum infection
Bacterial cellulitis

Workup

Laboratory Studies

  • Diagnosis of M kansasii infection requires isolation of the organism. Unlike other nontuberculous mycobacteria (NTM), M kansasii is believed to rarely represent colonization or an environmental contaminant.
  • Initially, evaluate at least 3 sputum samples by AFB staining and mycobacterial cultures. Bacteriologic examination may include AFB stain and culture of specimens (eg, bronchoalveolar lavage, aspirates from sterile sites, tissues).
  • Blood culture may be useful to detect M kansasii bacteremia and to establish a diagnosis of disseminated infection. Approximately 10% of patients with HIV infection who are also infected with M kansasii have blood cultures positive for M kansasii.
  • Nucleic acid probes and polymerase chain reaction (PCR) are useful for early identification of growing M kansasii colonies. They are highly sensitive and specific, providing species identification using a culture directly from BACTEC broth within 2-4 hours.
  • Susceptibility testing: The Clinical and Laboratory Standards Institute (CLSI) recommends that all initial isolates of M kansasii be tested only for rifampin susceptibility.7 Rifampin-susceptible isolates are also susceptible to rifabutin. If the isolate is resistant to rifampin, further susceptibility to rifabutin, isoniazid, streptomycin, clarithromycin, amikacin, ethambutol, trimethoprim-sulfamethoxazole, ciprofloxacin, moxifloxacin, and gatifloxacin should be determined. Rifampin-resistant isolates should be sent to an experienced reference laboratory for further testing.8 Ciprofloxacin susceptibility results mirror those of susceptibility for both ofloxacin and levofloxacin.
  • Interpretation of isoniazid susceptibility may be confusing because most M kansasii organisms show resistance to IN isoniazid H at 1 mcg/mL but are susceptible at 5 mcg/mL. The latter reflects a better correlation with in vivo isoniazid activity.
  • The currently available skin test is not helpful in establishing diagnosis.

Imaging Studies

  • Approximately 90% of patients with M kansasii disease have cavitary infiltrates on chest radiography. Among patients without cavitary lung lesions, clinical symptoms and high-resolution computed tomography (HRCT) scanning are important adjuncts in defining the presence of lung disease.

    Chest radiograph in a patient with <EM>Mycobacter...

    Chest radiograph in a patient with Mycobacterium kansasii pulmonary infection shows left lower lung infiltrates.

    Chest radiograph in a patient with <EM>Mycobacter...

    Chest radiograph in a patient with Mycobacterium kansasii pulmonary infection shows left lower lung infiltrates.


    Chest CT scan in a patient with <EM>Mycobacterium...

    Chest CT scan in a patient with Mycobacterium kansasii pulmonary infection (see Image 1).

    Chest CT scan in a patient with <EM>Mycobacterium...

    Chest CT scan in a patient with Mycobacterium kansasii pulmonary infection (see Image 1).


    Chest radiograph in a patient with classic right ...

    Chest radiograph in a patient with classic right upper lobe cavitary lung disease secondary to Mycobacterium kansasii infection (see Image 4 for CT thorax in the same patient). Courtesy of Raj Sreedhar, MD, SIU School of Medicine, Springfield, IL.

    Chest radiograph in a patient with classic right ...

    Chest radiograph in a patient with classic right upper lobe cavitary lung disease secondary to Mycobacterium kansasii infection (see Image 4 for CT thorax in the same patient). Courtesy of Raj Sreedhar, MD, SIU School of Medicine, Springfield, IL.


    CT thorax of a patient with classic right upper l...

    CT thorax of a patient with classic right upper lobe cavitary lung disease secondary to Mycobacterium kansasii infection (see Image 3 for the chest radiograph in the same patient). Courtesy of Raj Sreedhar, MD, SIU School of Medicine, Springfield, IL.

    CT thorax of a patient with classic right upper l...

    CT thorax of a patient with classic right upper lobe cavitary lung disease secondary to Mycobacterium kansasii infection (see Image 3 for the chest radiograph in the same patient). Courtesy of Raj Sreedhar, MD, SIU School of Medicine, Springfield, IL.

  • The characteristic radiological feature of M kansasii pulmonary infection has been described as a right-sided, apical or subapical, thin-walled cavitary infiltrate.4 In a separate study, which included only patients without HIV infection, a comparison of chest radiography findings in patients with M kansasii infection with those in patients with tuberculosis showed that M kansasii infection occurred more frequently as unilateral, right-sided infiltrates. Cavities were observed in both cases, whereas pleural effusions and air space shadowing involving multiple bronchopulmonary segments were less common in M kansasii infection.3
  • Analysis of chest radiographs in a series of 16 patients infected with HIV and M kansasii pulmonary infection showed the following abnormalities (in decreasing order of frequency):
    1. Alveolar opacities
    2. Cavity
    3. Thoracic lymphadenopathy
    4. Pleural effusions
    5. Interstitial opacities

Other Tests

  • Baseline laboratory workup for M kansasii infection should include complete blood cell count (CBC), renal profile, and liver profile.
  • Patients with M kansasii infection should be counseled about HIV infection and tested for HIV infection.
  • Perform a complete HIV evaluation if the patient tests positive for HIV. This evaluation should include CD4 counts and HIV viral load.

Procedures

  • Bronchoscopy, tissue biopsy, thoracentesis, or pericardiocentesis may be needed to recover the pathogen and establish diagnosis. In some cases, transthoracic needle aspiration or open-lung biopsy may be necessary.
  • Bone marrow and liver biopsies may be useful in establishing disseminated M kansasii infection.
  • Needle aspiration or biopsy of a skin lesion (eg, nodule) may be useful for establishing M kansasii skin infections.

Histologic Findings

The variable histopathologic findings of M kansasii disease may include acute suppuration, nonnecrotic tubercles, or caseation. In general, the findings are similar to tuberculosis.

Examination of lung tissue and lymph nodes usually shows caseating granulomas. Skin lesions may show granulomas with areas of necrosis or foci of acute and chronic inflammation without well-formed granulomas. Other tissues may show caseating or noncaseating granulomas.

AFB are commonly seen in tissues from lungs and lymph nodes. They are found less commonly in tissues from other sites.

In patients with AIDS or other immunocompromised states, many of the histologic characteristics usually associated with M kansasii infection may be absent. Cytologic and histologic material may show a wide range of inflammatory reactions, including granulomas with and without necrosis, neutrophilic abscesses, spindle-cell proliferation, and focal granular eosinophilic necrosis.9

Diagnostic Criteria Based on American Thoracic Society/Infectious Disease Society of America Guidelines

In 1997, the American Thoracic Society (ATS) established diagnostic criteria for NTM lung disease, regardless of the host's HIV status.10 These guidelines were revised and approved by the American Thoracic Society and Infectious Disease Society of America (IDSA) in 2007.

M kansasii is considered a highly pathogenic mycobacterium, and many experts advise that M kansasii isolated from lungs or elsewhere almost always warrants treatment, especially in patients with HIV/AIDS and in other immunocompromised groups. The authors of the ATS/IDSA guidelines also acknowledge and suggest that the treatment decisions for M kansasii should be made carefully, even if some specimens are not positive for M kansasii or if multiple specimens are not available, and they recommend expert consultation in the decision-making process.

The general diagnostic criteria for all NTM pulmonary infections based on 2007 ATS/IDSA guidelines are summarized below.11

Clinical criteria

Both of the following clinical criteria are required to establish a diagnosis of NTM lung disease:

  • Pulmonary symptoms, nodular or cavitary opacities on chest radiography, or a HRCT scan that shows multifocal bronchiectasis with multiple small nodules
  • Appropriate exclusion of other diagnoses

Microbiologic criteria

One of the following microbiologic criteria is required for diagnosis of NTM lung disease:

  • Positive culture results from at least 2 separate expectorated sputum samples (If these culture results are nondiagnostic, consider repeat sputum AFB smears and cultures.)
  • Positive culture result from at least one bronchial wash or lavage
  • Transbronchial or other lung biopsy sample with mycobacterial histopathologic features (granulomatous inflammation or AFB) and positive culture for NTM; alternatively, a biopsy sample showing mycobacterial histopathologic features (granulomatous inflammation or AFB) and one or more sputum or bronchial washings that are culture-positive for NTM

The ATS/IDSA guideline also recommends the followings for diagnosis:

  • Expert consultation should be obtained when NTM that are either infrequently encountered or that usually represent environmental contamination are recovered.
  • Patients with suspected NTM lung disease but who do not meet the diagnostic criteria should be observed until the diagnosis is firmly established or excluded.
  • A diagnosis of NTM lung disease does not automatically necessitate the institution of therapy, which is a decision based on potential risks and benefits of therapy in individual patients.

More on Mycobacterium Kansasii

Overview: Mycobacterium Kansasii
Differential Diagnoses & Workup: Mycobacterium Kansasii
Treatment & Medication: Mycobacterium Kansasii
Follow-up: Mycobacterium Kansasii
Multimedia: Mycobacterium Kansasii
References

References

  1. Bloch KC, Zwerling L, Pletcher MJ. Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study. Ann Intern Med. Nov 1 1998;129(9):698-704. [Medline].

  2. Corbett EL, Churchyard GJ, Hay M. The impact of HIV infection on Mycobacterium kansasii disease in South African gold miners. Am J Respir Crit Care Med. Jul 1999;160(1):10-4. [Medline].

  3. Evans AJ, Crisp AJ, Hubbard RB. Pulmonary Mycobacterium kansasii infection: comparison of radiological appearances with pulmonary tuberculosis. Thorax. Dec 1996;51(12):1243-7. [Medline].

  4. Maliwan N, Zvetina JR. Clinical features and follow up of 302 patients with Mycobacterium kansasii pulmonary infection: a 50 year experience. Postgrad Med J. 2005;81:530-33. [Medline].

  5. Evans SA, Colville A, Evans AJ. Pulmonary Mycobacterium kansasii infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis. Thorax. Dec 1996;51(12):1248-52. [Medline].

  6. Witzig RS, Fazal BA, Mera RM. Clinical manifestations and implications of coinfection with Mycobacterium kansasii and human immunodeficiency virus type 1. Clin Infect Dis. Jul 1995;21(1):77-85. [Medline].

  7. National Committee for Clinical Laboratory Standards. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard. M24-A. Wayne, PA: National Committee for Clinical Laboratory Standards; 2003.

  8. Woods GL. Susceptibility testing for mycobacteria. Clin Infect Dis. 2000;31:1209-1. [Medline].

  9. Smith MB, Molina CP, Schnadig VJ. Pathologic features of Mycobacterium kansasii infection in patients with acquired immunodeficiency syndrome. Arch Pathol Lab Med. 2003;127:554-60. [Medline].

  10. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med. Aug 1997;156(2 Pt 2):S1-25. [Medline].

  11. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. Feb 15 2007;175(4):367-416. [Medline].

  12. Griffith DE. Management of disease due to Mycobacterium kansasii. Clin Chest Med. 2002;23:613-21. [Medline].

  13. Guna R, Munoz C, Dominguez V. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii. J Antimicrob Chemother. 2005;55:950-53. [Medline].

  14. Marras TK, Morris A, Gonzalez LC. Mortality prediction in pulmonary Mycobacterium kansasii infection and human immunodeficiency virus. Am J Respir Crit Care Med. 2004;170:793-98. [Medline].

  15. Alcaide F, Benitez MA, Martin R. Epidemiology of Mycobacterium kansasii. Ann Intern Med. Aug 17 1999;131(4):310-1. [Medline].

  16. Breathnach A, Levell N, Munro C. Cutaneous Mycobacterium kansasii infection: case report and review. Clin Infect Dis. Apr 1995;20(4):812-7. [Medline].

  17. Davidson PT. The diagnosis and management of disease caused by M. avium complex, M. kansasii, and other mycobacteria. Clin Chest Med. Sep 1989;10(3):431-43. [Medline].

  18. Fishman JE, Schwartz DS, Sais GJ. Mycobacterium kansasii pulmonary infection in patients with AIDS: spectrum of chest radiographic findings. Radiology. Jul 1997;204(1):171-5. [Medline].

  19. O'Brien RJ. The epidemiology of nontuberculous mycobacterial disease. Clin Chest Med. Sep 1989;10(3):407-18. [Medline].

  20. Wolinsky E. Mycobacterial diseases other than tuberculosis. Clin Infect Dis. Jul 1992;15(1):1-10. [Medline].

  21. Woods GL, Meyers WM. Mycobacterial Diseases. In: Damjanov I, Linder J, eds. Anderson's Pathology. Vol 10. St. Louis, Mo: Mosby; 1996:843-55.

Further Reading

Keywords

Mycobacterium kansasii, M kansasii, acid-fast bacillus, AFB, nontuberculous mycobacterial infection, NTM infection, AIDS, Mycobacterium avium complex, MAC, M kansasii chronic pulmonary disease, pulmonary tuberculosis, cutaneous M kansasii infection, M kansasii nodule, M kansasii pustule, M kansasii verrucous lesion, M kansasii erythematous plaque, M kansasii abscess, M kansasii ulcer, M kansasii bacteremia, M kansasii pericarditis, M kansasii oral ulcer, chronic M kansasii sinusitis, M kansasii osteomyelitis, M kansasii scalp abscess

Contributor Information and Disclosures

Author

Janak Koirala, MD, MPH, FACP, Associate Professor, Department of Internal Medicine, Division of Infectious Diseases, Southern Illinois University School of Medicine
Janak Koirala, MD, MPH, FACP is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians-American Society of Internal Medicine, American Society for Microbiology, Infectious Diseases Society of America, International AIDS Society, International Society for Infectious Diseases, and International Society of Travel Medicine
Disclosure: Nothing to disclose.

Medical Editor

Klaus-Dieter Lessnau, MD, FCCP, Clinical Associate Professor of Medicine, New York University School of Medicine; Medical Director, Pulmonary Physiology Laboratory; Director of Research in Pulmonary Medicine, Department of Medicine, Section of Pulmonary Medicine, Lenox Hill Hospital
Klaus-Dieter Lessnau, MD, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Medical Association, American Society for Artificial Internal Organs, American Thoracic Society, Physicians for Social Responsibility, and Society of Critical Care Medicine
Disclosure: sepracor Ownership interest None

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Aaron Glatt, MD, Professor of Clinical Medicine, New York Medical College; President and CEO, Former Chief Medical Officer, Departments of Medicine and Infectious Diseases, New Island Hospital
Aaron Glatt, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physician Executives, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Medical Association, American Society for Microbiology, American Thoracic Society, American Venereal Disease Association, Infectious Diseases Society of America, International AIDS Society, and Society for Healthcare Epidemiology of America
Disclosure: Nothing to disclose.

CME Editor

Eleftherios Mylonakis, MD, Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital
Eleftherios Mylonakis, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Microbiology, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

Chief Editor

Burke A Cunha, MD, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital
Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.